Skip to content

Role of Hypertonic Saline Versus Mannitol in the Management of Raised Intracranial Pressure in Patients With ALF

Role of Hypertonic Saline Versus Mannitol in the Management of Raised Intracranial Pressure in Patients With ALF: A Randomized Open -Label Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02460510
Enrollment
52
Registered
2015-06-02
Start date
2014-06-30
Completion date
2015-11-30
Last updated
2016-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Liver Failure

Brief summary

Patients with ALF (Acute liver Failure) would undergo a detailed clinical evaluation. Information would be collected regarding the onset and duration of symptoms, etiology, and severity of disease, other baseline clinical features, demographic characteristics, routine biochemical and hematological investigations. Patients would also be screened for the assessment of raised intracranial hypertension by either clinical or neuroimaging or by ONSD (optic nerve sheath diameter) and TCD (Transcranial doppler ultrasonography). Patient found to be having risen ICP (Intra Cranial Pressure) would be randomized in the two groups of the study. The group A would receive intravenous mannitol 20 to 30 minutes every 4 hourly where as those in the group B would be given 3% hypertonic saline as continuous infusion at a rate of 25ml /hr and titrated q4 hrs per sliding scale to achieve a target serum sodium level of 144-155 mmol/L .Both the groups would receive other supportive measures such as head end elevation, oxygen supplementation, dextrose infusion to maintain normoglycemia standard medical treatment.

Interventions

DRUGMannitol

Sponsors

Institute of Liver and Biliary Sciences, India
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients with Acute Liver Failure with age \>18 yrs * Grade III or grade IV HE with raised ICP * Patient's next-of-kin consenting for the study protocol.

Exclusion criteria

* Patients with ocular trauma. * K/c/o DCM, congestive heart failure, cerebral aneurysm, intracranial pathology * Serum Na\>160 and s creat\>1.5 mg% with oligurea

Design outcomes

Primary

MeasureTime frameDescription
To study response to therapy at 12 hr in HTS Vs mannitol group in reduction of ICP (Intra Cranial Pressure)12 hoursICP (Intra Cranial Pressure) as assessed by ONSD (Optic Nerve Sheet Diameter) \< 5mm PS\<1.2 Pupils - RTL(reaction to light) {if initially NTR(no reaction to light)} BP\<150/90(if initially high) Pulse \>60( if \< 60)

Secondary

MeasureTime frame
Correlation of arterial NH3 to raised ICT (Intra cranial Tension).2 years
Survival.28 days
Length of ICU/hospital stay.2 years

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026